Best Telehealth Clinics in Massachusetts (2026)

Massachusetts enacted Chapter 260 of the Acts of 2020 ("An Act Promoting a Resilient Health Care System That Puts Patients First"), signed on January 1, 2021, as bill S.2769 of the 191st General Court. This established telehealth coverage parity, audio-only coverage, and remote patient monitoring. The law also included surprise billing protections, an unusual bundled approach.

No explicit state-level in-person requirement was identified for telehealth prescribing of controlled substances in Massachusetts. The state relies on the federal DEA framework. Controlled substances (Schedules II through V) are governed by M.G.L. c. 94C and 247 CMR 9.04 (pharmacy dispensing regulations). The federal DEA waiver through December 2026 allows telehealth prescribing of Schedule II through V substances without in-person visits.

Chapter 260 made certain expansions permanent. Mental health telehealth parity is permanent. Chronic disease and primary care parity required periodic reauthorization. MassHealth (Medicaid) implemented permanent telemedicine coverage rules separately through administrative action. Massachusetts has not enacted a single permanent omnibus telehealth bill equivalent to Arizona's HB 2454 or Washington's ESSB 5481.

Massachusetts is not a member of the Interstate Medical Licensure Compact. IMLC legislation has been introduced but has not been enacted as of April 2026. This is a significant limitation: providers cannot use the IMLC expedited pathway to add Massachusetts. Every telehealth provider serving MA needs a separate Massachusetts medical license, similar to California and New York.

Massachusetts has a state Schedule VI classification for non-federally scheduled controlled substances. These have different prescribing and dispensing rules than federally controlled substances and may allow more flexibility in telehealth settings. Electronic prescribing of Schedules II through V requires a DEA-compliant e-prescribing system. Schedule III through V oral call-in prescriptions require a written follow-up within seven days.

Massachusetts has 7.0 million residents and is the sixteenth-largest state. Provider availability is moderate, limited by the lack of IMLC membership. Of the 64 providers tracked, roughly 50 to 53 serve Massachusetts.

All-50-state providers like Maximus ($100/mo with labs), Hone Health ($25/mo entry), and Sesame Care serve Massachusetts without issue. TRT Nation ($99/mo, 45 states) includes MA. Providers listing "Most US states" like BraverX ($129/mo), PeterMD ($99/mo annual), DudeMeds ($77/mo), and Titan Medical ($99/mo) generally include MA, but the separate licensing requirement means some newer or smaller providers may skip the state.

GLP-1 availability is good. Embody, SkinnyRx, DirectMeds, Zealthy, Remedy Meds, GobyMeds, Shed, MEDVi, Sunlight, and Mochi Health serve Massachusetts. Massachusetts is notable for MassHealth's GLP-1 coverage for weight loss, though the policy has been volatile.

All HRT providers serve the state. Midi Health accepts insurance. PlushCare accepts major insurers. All hair loss and ED providers serve Massachusetts.

Enhance MD's 11-state exclusion list may include MA. Limitless TRT operates in "select states" and likely does not include MA. Peptide provider availability is moderate.

TRT pricing matches national rates. DudeMeds: $77/mo ($1,124/year). TRT Nation: $99/mo ($1,446/year). PeterMD: $99/mo annual ($1,188/year). Maximus: $100/mo annual ($1,300/year). BraverX: $129/mo ($1,548/year). Defy Medical: $200/mo ($2,800/year).

GLP-1 ranges from $99/mo to $399/mo. GobyMeds at $119/mo and Fridays at $117/mo are budget options. Median is $179/mo.

MassHealth (Massachusetts Medicaid) has the most volatile GLP-1 coverage history of any state. As of January 1, 2025, MassHealth designated Wegovy and Saxenda as non-covered for adult obesity. Then reversed: as of January 2026, Wegovy was added back as a preferred drug at parity with Zepbound. Prior authorization is required. BMI must be 30 or higher, or 27 or higher with a weight-related comorbidity. Phentermine trial is no longer required before GLP-1 initiation (removed in 2025 policy update). Patients should verify current MassHealth coverage before assuming access, given the policy changes.

Massachusetts does not tax prescription medications. The state sales tax is 6.25% but Rx drugs are exempt. Massachusetts has a relatively high cost of living, but telehealth pricing is national.

HRT: Midi Health (insurance), PlushCare ($20/mo), Evernow ($35/mo), Alloy ($49/mo). ED: Hims $17/mo to MEDVi $119/mo.

TRT (testosterone replacement therapy)

No state-specific in-person requirement identified for TRT prescribing via telehealth. Massachusetts relies on the federal DEA framework, which permits telehealth prescribing of Schedule III substances through December 2026. Both compounded and FDA-approved testosterone are available. Electronic prescribing is required for Schedule II through V. The lack of IMLC membership limits the provider pool compared to compact member states.

GLP-1 weight loss

No state-specific restrictions on semaglutide or tirzepatide. Federal FDA compounding rules apply. The Massachusetts Board of Registration in Pharmacy issued guidance bulletins on GLP-1 compounding in November 2024 and April 2025, tracking federal enforcement. MassHealth covers Wegovy and Zepbound for obesity as of January 2026 with prior authorization, making MA one of the more accessible states for Medicaid GLP-1 coverage.

HRT (hormone replacement therapy)

HRT follows standard federal prescribing rules in Massachusetts. No additional state restrictions apply. All HRT providers serve the state.

Hair loss

Hair loss treatment follows standard federal prescribing rules in Massachusetts. No additional state restrictions apply.

ED (erectile dysfunction)

ED treatment follows standard federal prescribing rules in Massachusetts. No additional state restrictions apply.

Peptides

Peptide therapy follows standard federal rules in Massachusetts. No state-specific peptide restrictions identified. The lack of IMLC membership may limit peptide provider availability compared to compact states.